Figure 2.

Subcutaneous and metastatic PHEO in mouse model suitable for immunotherapy testing established using MTT-luciferase cells. (A) B6(Cg)-Tyr^c-2J/J mice were subcutaneously (n = 24) or intravenously (n = 10) injected with MTT-luciferase cells. (B) Subcutaneous MTT-luciferase tumors reached a mean volume of 118 mm³ 45 days after tumor cell injection. No tumors were detected for 30 days after tumor cells injection. (C) Metastatic organ lesions were detectable 14 days after intravenous tumor cells injection using bioluminescence imaging. Metastatic organ lesions were predominantly located in the liver; small lesions were also detected in bones and lymph nodes. (D) Tumor-bearing mice, either with subcutaneous tumors or metastatic organ lesions, had significantly higher urine norepinephrine levels than those without tumors (* p < 0.05; ** p < 0.01 against no tumor).